Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 6/20 | 0.62 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | CDK7 | P50613 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30491303 | 1.00 | MAPK1 (0.62) | MAPK1DAOJAK2JAK3ABL1 | |
| SCHEMBL13199608 | 0.77 | JAK2 (0.40) | MAPK1DAOJAK2JAK3 | |
| SCHEMBL30491243 | 0.77 | MAPK1 (0.62) | MAPK1JAK2JAK3ABL1RET | |
| SCHEMBL29488969 | 0.77 | MAPK1 (1.00) | MAPK1JAK2JAK3ABL1RET | |
| SCHEMBL14331928 | 0.77 | MAPK1 (0.62) | MAPK1ABL1RETKDRCDK7 | |
| SCHEMBL25257114 | 0.77 | MAPK1 (0.62) | MAPK1ABL1RETKDRCDK7 | |
| SCHEMBL2378181 | 0.77 | MAPK1 (0.62) | MAPK1JAK2JAK3ABL1RET | |
| SCHEMBL649129 | 0.77 | MAPK1 (1.00) | MAPK1JAK2JAK3ABL1RET | |
| SCHEMBL1352440 | 0.73 | MAPK1 (0.57) | MAPK1CDK5 | |
| SCHEMBL25302723 | 0.73 | MAPK1 (0.57) | MAPK1JAK2JAK3ABL1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023131122-A1 | FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131122-A1 | FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| EP-3430005-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS THEREFORE | PLEXXIKON INC (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-3430005-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS THEREFORE | Plexxikon Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| US-10160747-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-12-25 | — | — | US | disclosed |
| WO-2017161045-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS THEREFORE | PLEXXIKON INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20170267660-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170267660-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-09-21 | — | — | US | disclosed |
| WO-2017161045-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS THEREFORE | PLEXXIKON INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| CN-102232076-A | Pyrrolopyrazinyl urea kinase inhibitors | HOFFMANN LA ROCHE | 2011-11-02 | — | — | CN | disclosed |
| EP-2373653-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2010063634-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267660-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKAR2B, AKT3, MAP3K11 | MAPK1 94/4885DAO 3972/4885JAK2 163/4885 |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | JAK1, JAK3, ULK3 | MAPK1 234/4885DAO 3032/4885JAK2 5/4885 |
| US-10160747-B2 | Compounds and methods for kinase modulation, and indications therefor | PRKAR2B, AKT3, MAP3K11 | MAPK1 94/4885DAO 3972/4885JAK2 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.